Get the Stockscreener App
64.96
0.90%
-0.63
Kymera Therapeutics Inc stock is traded at $64.96, with a volume of 392.59K.
It is down -0.90% in the last 24 hours and up +11.00% over the past month.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
See More
Previous Close:
$65.59
Open:
$65.8
24h Volume:
392.59K
Relative Volume:
0.52
Market Cap:
$4.68B
Revenue:
$58.89M
Net Income/Loss:
$-240.88M
P/E Ratio:
-20.95
EPS:
-3.1
Net Cash Flow:
$-239.96M
1W Performance:
+1.08%
1M Performance:
+11.00%
6M Performance:
+120.42%
1Y Performance:
+38.24%
1-Day Range:
$63.86
$67.19
1-Week Range:
$63.77
$68.80
52-Week Range:
$19.45
$68.80
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Name
Kymera Therapeutics Inc
Sector
Industry
Phone
857-285-5314
Address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
65.01 | 4.72B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
428.94 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
782.23 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.13 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
908.04 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.22 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Resumed | Guggenheim | Buy |
| Oct-24-25 | Reiterated | B. Riley Securities | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-18-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-16-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jun-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-02-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-20-25 | Resumed | Stifel | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-26-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-22-24 | Initiated | Oppenheimer | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Jan-04-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-30-23 | Initiated | Truist | Buy |
| May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-06-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-08-22 | Initiated | Raymond James | Mkt Perform |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Aug-03-22 | Initiated | Goldman | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | JP Morgan | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Sep-30-21 | Initiated | B. Riley Securities | Neutral |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Sep-15-20 | Initiated | BofA Securities | Neutral |
| Sep-15-20 | Initiated | Cowen | Outperform |
| Sep-15-20 | Initiated | Guggenheim | Buy |
| Sep-15-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Kymera Therapeutics Inc Stock (KYMR) Latest News
Truist Securities Raises Price Target on Kymera Therapeutics to $80 From $68, Maintains Buy Rating - MarketScreener
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader - Investing News Network
Kymera Therapeutics Begins Dosing Patients in Phase 2 Trial of Potential Dermatitis Treatment - MarketScreener
Kymera Therapeutics (KYMR) Advances STAT6 Degrader Program with New Trial - GuruFocus
Kymera initiates phase 2b trial of oral STAT6 degrader for atopic dermatitis - Investing.com Australia
Kymera initiates phase 2b trial of oral STAT6 degrader for atopic dermatitis By Investing.com - Investing.com South Africa
Kymera Therapeutics Advances KT-621 Trials with Upcoming Phase 1b Data in Atopic Dermatitis and Phase 2b Initiation for Asthma - Quiver Quantitative
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader - GlobeNewswire Inc.
Kymera Therapeutics stock hits 52-week high at 68.65 USD By Investing.com - Investing.com Nigeria
Kymera Therapeutics stock hits 52-week high at 68.65 USD - Investing.com India
Universal Beteiligungs und Servicegesellschaft mbH Purchases 22,392 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics to Participate in Upcoming December Investor Conferences - The Manila Times
SG Americas Securities LLC Buys Shares of 22,065 Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics (NASDAQ: KYMR) to Present at Piper Sandler, Citi and Evercore Events - Stock Titan
Neo Ivy Capital Management Purchases 6,079 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
Will Kymera Therapeutics Inc. stock benefit from infrastructure spendingWeekly Trading Summary & Safe Entry Momentum Stock Tips - newser.com
Kymera at Jefferies Conference: Targeted Protein Degradation Focus - Investing.com India
Kymera at Jefferies Conference: Targeted Protein Degradation Focus By Investing.com - Investing.com Canada
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is Kymera Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Update & Technical Buy Zone Confirmation - newser.com
Kymera Therapeutics (NASDAQ:KYMR) Hits New 52-Week HighStill a Buy? - MarketBeat
Behavioral Patterns of KYMR and Institutional Flows - news.stocktradersdaily.com
Candriam S.C.A. Invests $6.73 Million in Kymera Therapeutics, Inc. $KYMR - MarketBeat
How analysts rate Kymera Therapeutics Inc. stock todayJuly 2025 Highlights & Expert Approved Momentum Ideas - newser.com
Stifel reiterates Buy rating on Kymera Therapeutics stock ahead of December data - Investing.com Canada
Is Kymera Therapeutics Inc. stock supported by innovation pipelineJuly 2025 Price Swings & Capital Efficiency Focused Strategies - newser.com
Why Kymera Therapeutics Inc. stock could outperform in 2025Trade Risk Summary & Weekly Top Performers Watchlists - Fundação Cultural do Pará
How to read the order book for Kymera Therapeutics Inc.Bear Alert & Low Risk High Reward Trade Ideas - newser.com
Kymera at TD Cowen Summit: Strategic Moves in Immunology By Investing.com - Investing.com Canada
What analysts say about Kymera Therapeutics Inc stockMoving Average Crossovers & Subscribe for Free Weekly Winners - earlytimes.in
What valuation multiples suggest for Kymera Therapeutics Inc. stock2025 Year in Review & Reliable Volume Spike Trade Alerts - newser.com
What drives Kymera Therapeutics Inc stock priceStock Liquidity Analysis & Free Rapid Growing Investment Returns - earlytimes.in
Kymera Therapeutics stock hits 52-week high at 64.0 USD By Investing.com - Investing.com Philippines
Kymera added to Citi catalyst watch list on atopic dermatitis asset data readout - MSN
Kymera at Stifel Conference: Strategic Insights on Drug Development By Investing.com - Investing.com UK
Kymera Therapeutics stock hits 52-week high at 64.0 USD - Investing.com
Kymera Therapeutics soars 35% on positive phase 1 results for oral STAT6 degrader KT-621 - MSN
Pattern recognition hints at Kymera Therapeutics Inc. upsideAnalyst Downgrade & Reliable Price Action Trade Plans - newser.com
Transcript : Kymera Therapeutics, Inc. Presents at UBS Global Healthcare Conference 2025, Nov-10-2025 11 - MarketScreener
What is HC Wainwright's Forecast for KYMR FY2025 Earnings? - MarketBeat
Equities Analysts Set Expectations for KYMR FY2025 Earnings - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Upgraded at Wall Street Zen - MarketBeat
Kymera Therapeutics (KYMR) Gets a Buy from RBC Capital - The Globe and Mail
Kymera Therapeutics’ Earnings Call Highlights Growth and Challenges - MSN
Wells Fargo & Company Forecasts Strong Price Appreciation for Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Kymera Therapeutics Reports Q3 2025 Financial Results - MSN
Truist Financial Keeps Their Buy Rating on Kymera Therapeutics (KYMR) - The Globe and Mail
HC Wainwright & Co. Maintains Kymera Therapeutics (KYMR) Buy Recommendation - MSN
Kymera upped to overweight by Wells Fargo on upcoming data - MSN
Barclays Maintains Kymera Therapeutics (KYMR) Overweight Recommendation - Nasdaq
Kymera Therapeutics Inc Stock (KYMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):